TEXARKANA, Texas — Benign prostatic hyperplasia — or BPH — is a common condition in men over 50 that causes the prostate to enlarge. The enlarged prostate pinches the urethra, which carries urine from ...

Teleflex TFX recently announced the upcoming full market release of the Advanced Tissue Control (“ATC”) feature on its unified UroLift 2 System — a platformdesigned for the treatment of benign ...

Highlights include two head-to-head randomized clinical trials (RCT) data presentations of UroLift™ System vs. other modalities to treat benign prostatic hyperplasia (BPH) - Additional studies examine ...

UroLift is a minimally invasive treatment option for benign prostatic hyperplasia (BPH), also called enlarged prostate. Medicare covers the UroLift procedure when a doctor deems it medically necessary ...

For millions of older American men, it’s assumed that more frequent urination is simply part of the aging process. However, what they may not know is that there are treatments available to them to ...

Urolift is a minimally invasive procedure to help treat an enlarged prostate, known as benign prostatic hyperplasia (BPH). Medicare will typically cover Urolift procedures when a doctor deems them ...

WAYNE, Pa., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Teleflex Incorporated (TFX) (NYSE:TFX), a leading global provider of medical technologies, announced today that a new peer-reviewed study in the Nature ...

Teleflex announces favorable results for UroLift™ in treating BPH, showing higher patient satisfaction and better early recovery compared to Rezūm. Teleflex Incorporated announced new results from the ...

WAYNE, Pa., May 07, 2024 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a global leader in medical technologies, today announced the presentation of new research findings from the 2024 ...

Rates of surgical retreatment, alongside patient experience factors such as complications and adverse events (AEs), are important considerations when patients and their providers assess BPH therapies.